A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Unless the context otherwise requires, all references in this section to the “Company,” “Ginkgo,” “we,” “us,” or “our” refer to the business of Ginkgo Bioworks Holdings, Inc. and our subsidiaries. Overview: Our Mission is to Make Biology Easier to Engineer Our mission is to make biology easier to engineer. That has never changed. Every choice we’ve made with respect to our business model, our platform, our people, and our culture is grounded in whether it will advance our mission. Why? Because: 1.Biology is programmable. All living things run on the same DNA code. 2.Biology matters. The ability to engineer biology has had and will have a profound impact on how we develop new medicines and vaccines, grow our food, and manufacture many of the things we use every day. 3.Biology is hard. Today, it is still too difficult and too costly to engineer biology, preventing critical innovations from reaching the market.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 170M | 170M | - | - | - | - |
| Net Income | -313M | -313M | -547M | -893M | -2.1B | -1.8B |
| EPS | $-5.64 | $-5.64 | $-10.54 | $-18.37 | $-50.00 | $-55.60 |
| Free Cash Flow | -179M | -179M | -382M | -336M | -304M | -310M |
| ROIC | -73.0% | -61.5% | -76.4% | -81.4% | -100.5% | -69.7% |
| Gross Margin | 81.5% | 81.5% | - | - | - | - |
| Debt/Equity | 0.00 | 1.20 | 0.92 | 0.52 | 0.46 | 0.01 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -315M | -315M | -560M | -864M | -2.2B | -1.8B |
| Operating Margin | -185.3% | -185.3% | - | - | - | - |
| ROE | -61.5% | -51.1% | -76.4% | -81.4% | -121.2% | -121.6% |
| Shares Outstanding | 55M | 55M | 52M | 49M | 42M | 33M |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | |||
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | N/A | 77M | N/A | N/A | N/A | N/A | 170M | 170M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | 81.5% | 81.5% |
| R&D | 96M | 160M | 1.1B | 1.1B | 581M | 424M | 244M | 244M |
| SG&A | 29M | 38M | 863M | 1.4B | 385M | 246M | 183M | 183M |
| EBIT | -72M | -137M | -1.8B | -2.2B | -864M | -560M | -315M | -315M |
| Op. Margin | N/A | -178.8% | N/A | N/A | N/A | N/A | -185.3% | -185.3% |
| Net Income | -119M | -127M | -1.8B | -2.1B | -893M | -547M | -313M | -313M |
| Net Margin | N/A | -165.2% | N/A | N/A | N/A | N/A | -183.8% | -183.8% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 72M | 11M | 11M |
| Returns on Capital | ||||||||
| ROIC | N/A | -26.5% | -69.7% | -100.5% | -81.4% | -76.4% | -61.5% | -73.0% |
| ROE | N/A | -26.3% | -121.6% | -121.2% | -81.4% | -76.4% | -51.1% | -61.5% |
| ROA | -23865.4% | -37.5% | -88.4% | -82.9% | -53.6% | -39.7% | -25.0% | -27.9% |
| Cash Flow | ||||||||
| Op. Cash Flow | -45M | -136M | -254M | -252M | -296M | -320M | -171M | -171M |
| Free Cash Flow | -67M | -194M | -310M | -304M | -336M | -382M | -179M | -179M |
| Owner Earnings | -56M | -170M | -1.9B | -2.2B | -596M | -495M | -312M | -312M |
| CapEx | 22M | 58M | 57M | 52M | 41M | 63M | 7.7M | 7.7M |
| Maint. CapEx | 11M | 34M | 29M | 43M | 71M | 63M | 59M | 59M |
| Growth CapEx | 11M | 24M | 27M | 9.7M | 0 | 0 | 0 | 0 |
| D&A | 11M | 34M | 29M | 43M | 71M | 63M | 59M | 59M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 408K | 0 | 25M | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | 0.2% | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 771K | 476K | 1.6B | 1.9B | 230M | 112M | 82M | 82M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||||
| Net Debt | N/A | -364M | -3.1B | N/A | N/A | N/A | N/A | -167M |
| Cash & Equiv. | 495M | 381M | 1.6B | 1.3B | 944M | 562M | 167M | 167M |
| Long-Term Debt | N/A | 17M | 22M | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | N/A | 0.04 | 0.01 | 0.46 | 0.52 | 0.92 | 1.20 | 0.00 |
| Interest Coverage | -29.6 | -57.5 | -770.5 | -20839.2 | -9294.7 | -5954.9 | N/A | N/A |
| Equity | N/A | 461M | 1.5B | 1.7B | 1.1B | 716M | 509M | 509M |
| Total Assets | 500K | 675M | 2.1B | 2.5B | 1.7B | 1.4B | 1.1B | 1.1B |
| Total Liabilities | N/A | 205M | 504M | 803M | 568M | 661M | 611M | 611M |
| Intangibles | N/A | 5.2M | 43M | 171M | 132M | 145M | 114M | 114M |
| Retained Earnings | N/A | -468M | -2.3B | -4.4B | -5.3B | -5.8B | -6.2B | -6.2B |
| Working Capital | N/A | 353M | 1.6B | 1.3B | 838M | 495M | 376M | 376M |
| Current Assets | 2.4M | 427M | 1.7B | 1.5B | 1.0B | 603M | 472M | 472M |
| Current Liabilities | N/A | 73M | 135M | 173M | 164M | 107M | 96M | 96M |
| Per Share Data | ||||||||
| EPS | -4.00 | -4.00 | -55.60 | -50.00 | -18.37 | -10.54 | -5.64 | -5.64 |
| Owner EPS | -1.88 | -5.37 | -57.39 | -52.86 | -12.26 | -9.54 | -5.62 | -5.62 |
| Book Value | N/A | 14.58 | 45.74 | 41.24 | 22.57 | 13.80 | 9.17 | 9.17 |
| Cash Flow/Share | -1.50 | -4.29 | -7.71 | -5.99 | -6.08 | -6.16 | -3.08 | -4.58 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 29.8M | 31.7M | 32.9M | 42.1M | 48.6M | 51.9M | 55.5M | 55.5M |
| Valuation | ||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -1.4 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | 8.0 | 1.6 | 3.1 | 0.7 | 0.9 | 0.8 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | 3.3 | 2.5 |
| FCF Yield | N/A | N/A | -2.6% | -11.0% | -9.8% | -76.2% | -38.4% | -41.7% |
| Market Cap | N/A | N/A | 12.0B | 2.8B | 3.4B | 501M | 466M | 428M |
| Avg. Price | N/A | N/A | 432.34 | 135.69 | 65.98 | 25.00 | 10.21 | 7.72 |
| Year-End Price | N/A | N/A | 366.00 | 66.00 | 70.80 | 9.66 | 8.40 | 7.72 |
Ginkgo Bioworks Holdings, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 81.5%.
Ginkgo Bioworks Holdings, Inc. (DNA) has a 5-year average return on invested capital (ROIC) of -77.9%. This is below average and may indicate limited pricing power.
Ginkgo Bioworks Holdings, Inc. (DNA) has a market capitalization of $428M. It is classified as a small-cap stock.
Ginkgo Bioworks Holdings, Inc. (DNA) does not currently pay a regular dividend.
Ginkgo Bioworks Holdings, Inc. (DNA) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Ginkgo Bioworks Holdings, Inc. (DNA) reported annual revenue of $170 million in its most recent fiscal year, based on SEC EDGAR filings.
Ginkgo Bioworks Holdings, Inc. (DNA) has a net profit margin of -183.8%. The company is currently unprofitable.
Ginkgo Bioworks Holdings, Inc. (DNA) generated $-179 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Ginkgo Bioworks Holdings, Inc. (DNA) has a debt-to-equity ratio of 1.20. This indicates moderate leverage.
Ginkgo Bioworks Holdings, Inc. (DNA) reported earnings per share (EPS) of $-5.64 in its most recent fiscal year.
Ginkgo Bioworks Holdings, Inc. (DNA) has a return on equity (ROE) of -51.1%. A negative ROE may indicate losses or negative equity.
Ginkgo Bioworks Holdings, Inc. (DNA) has a 5-year average gross margin of 81.5%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 7 years of financial data for Ginkgo Bioworks Holdings, Inc. (DNA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Ginkgo Bioworks Holdings, Inc. (DNA) has a book value per share of $9.17, based on its most recent annual SEC filing.